Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2017

Herpes Zoster y Tofacitinib en Pacientes con Artritis Reumatoide

Arthritis Rheumatol 2014;66:2675–84

Chew R,

Patients who were treated with tofacitinib in the RA clinical development programme were more likely to develop herpes zoster than were those who received placebo.Cases of herpes zoster reported by investigators in the Phase 2, Phase 3 and long-term extension studies of tofacitinib were evaluated. Herpes zoster was noted in 5% of tofacitinib-treated patients; only 7% of these cases were serious, no patients with herpes zoster died and only 10% permanently discontinued tofacitinib treatment.The o...

Keywords:

July 2017

Seguridad a largo plazo de Tofacitinib para el Tratamiento de la Artritis Reumatoide hasta 8.5 años. Análisis integrado de datos de los Ensayos Clínicos Mundiales

Ann Rheum Dis 2017;76:1253-1262. DOI 10.1136/annrheumdis-2016-210457

Lee EB,

Nash P,

Geier J,

Kwok K,

Wang L,

Riese R,

Wollenhaupt J

This analysis of exposure to tofacitinib, an oral JAKi for the treatment of RA, for up to 8.5 years allowed estimation of safety events with improved precision versus previous tofacitinib reports. Adverse events were generally stable over time; no new safety signals were observed compared with previous tofacitinib reports.Data were collated into an integrated safety summary of tofacitinib in adult patients with active RA, and included data spanning the tofacitinib clinical programme: from 2 Pha...